CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 30 enrolled
Drug / intervention
19(T2)28z1xx CAR T cellsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04464200
NCT04464200Phase 1Active
CompareCT.gov

A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 9, 2020·Updated Aug 24, 2025

In Brief

A Phase 1 clinical trial evaluating 19(T2)28z1xx CAR T cells for Diffuse Large B Cell Lymphoma and 8 related conditions. Active but no longer recruiting, targeting 30 participants across 7 sites.

Detailed Summary

The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they can test it in future participants to see if it is effective in treating their relapsed/refractory B-cell cell cancers. This study will also look at whether 19(T2)28z1xx CAR T cells work against participants' cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
CountriesUnited States
CollaboratorsTakeda

Timeline

Phase 1ActiveOverdue
202120222023202420252026
First PostedJul 9, 2020
Enrollment StartJul 6, 2020
Primary CompletionJul 1, 2026
TodayJul 1, 2026
Enrollment to primary: 6.0 yearsPosted 6.0 years ago

Interventions

19(T2)28z1xx CAR T cellsdrug

2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.